Table 2 Summary of immunohistochemical and Epstein–Barr virus RNA in‐situ hybridisation results in nasal natural killer/T‐cell lymphomas.

Case	CD3	CD4	CD8	CD79a	CD56	CD57	CD3e	TIA‐1	EBER (%)*	Type	F/“f”	I/“i”	XhoI
1	++	+/−	++	−†	−	−	++	++	80	1	F	“i”	Loss
2	++‡	−	−	−†	++	−	++	++	90<	1	F	NA	Wild type
3	−†	−	−§	−†	++	−	−§	++	90<	1	F	NA	Loss
4	++‡	−†	−†	−†	++	−§	++	++	80	NA	“f”	NA	NA
5	++	−§	++	−†	−	−†	+	++	70	1	F	“i”	Loss
6	++‡	−	−†	−	++	−§	++	++	0	NT	NT	NT	NT
7	−§	−	−§	−†	++	NT	++	++	0	NT	NT	NT	NT
8	−§	−	+	−	+	NT	++	++	90<	1	F	“i”	Loss
9	+‡	−	++	−†	−	NT	++	++	70	1	F	“i”	Wild type

EBER, Epstein–Barr virus‐encoded small RNA; NA, not amplified; NT, not tested.

*In‐situ hybridisation results were expressed as number of positive cells per medium‐powered field (×200). Cases were considered positive when a positive signal was observed in ⩾10% of the tumour cells.

†Background was also reacted.

‡Cytoplasmic expression was observed.

§Positive for reactive cells but not for neoplastic cells.